In Hawaii, Compound Laws tracks 19 compounds: 8 legal to sell at retail, 1 restricted, 0 in a gray area, 5 illegal, and 5 whose status varies by product form. Verified through October 22, 2026.
235db61e54f06edcSale, hold for sale, offer or distribute of the following is PROHIBITED: Crude extract or MHP that is adulterated or misbranded; Crude extract or MHP that fails to meet applicable testing requirements; Any food into which a cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, hemp, hemp biomass, or MHP has been added as ingredient (this does not apply to hemp that is GRAS by FDA for use in foods, nor allowable edible MHP forms that are compliant with Sec.11-37-5: tablets, capsules, powders, softgels, gelcaps, oil-based tinctures, gummies, beverages); Crude extract or MHP that has total THC concentration above 0.3%; Vape or other product used to aerosolize for respiratory routes of delivery containing hemp-derived cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, or hemp; Hemp leaf, hemp floral material, including but not limited to hemp cigars or hemp cigarettes, viable seeds (this does not apply to sale of hemp leaf, hemp floral material, or viable seeds to a USDA licensed hemp producer or a DOH permitted hemp processor); MHP containing any viable seeds, leaf or floral materials; Except for external topically applied MHP, any product containing a hemp-derived cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, hemp, hemp biomass, or MHP as an ingredient intended to be introduced via non-oral routes of entry to body (i.e. eyes, ears and nasal cavities, etc.); Crude extract directly to a consumer (crude extract shall only be sold to a permitted hemp processor or person with equivalent authority from regulatory agency in another jurisdiction); Contents from an open package of MHP to a consumer; Advertising, packaging, labeling that contains health or benefit claims that are unsubstantiated, false, or misleading in any way. DOH implementing guidance (Consumers of MHP FAQ, current 12/16/2025): 'Hawaii prohibits the sale of MHP that contain artificially derived or synthetic cannabinoids. This includes cannabinoids like delta-8 THC, delta-10 THC, THCO, THC-P, THC-H, THCjd, HHC, HHCO, CBN created from any naturally occurring cannabinoid, like CBD, that was extracted from hemp biomass, or using a non-hemp substance, like yeast or algae, to produce any cannabinoid. State law only allows for cannabinoids naturally occurring in hemp to be extracted for use in manufactured hemp products.'
7e1f52470eecfb58§11-37-3 Prohibitions. ... (e) [No person shall sell, hold for sale, offer, or distribute] "any other product containing hemp used to aerosolize for respiratory routes of delivery, such as an inhaler, vape pen" [or other device designed for such purpose.] (f) "No person shall sell, hold for sale, offer, or distribute any hemp leaf, hemp floral material," "including but not limited to hemp cigars or hemp cigarettes, or viable hemp seeds" [...]. (h) [Products intended for] "non-oral routes of entry to the body" [are prohibited, with listed exceptions]. §11-37-11(a) "Beginning January 1, 2026, no manufactured hemp product distributor or manufactured hemp product retailer shall sell" [manufactured hemp products] "without a certificate of registration." [Bracketed spans summarized; the DOH compilation is stamped JAN 28 2026.]
235db61e54f06edcSale, hold for sale, offer or distribute of the following is PROHIBITED: Crude extract or MHP that is adulterated or misbranded; Crude extract or MHP that fails to meet applicable testing requirements; Any food into which a cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, hemp, hemp biomass, or MHP has been added as ingredient (this does not apply to hemp that is GRAS by FDA for use in foods, nor allowable edible MHP forms that are compliant with Sec.11-37-5: tablets, capsules, powders, softgels, gelcaps, oil-based tinctures, gummies, beverages); Crude extract or MHP that has total THC concentration above 0.3%; Vape or other product used to aerosolize for respiratory routes of delivery containing hemp-derived cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, or hemp; Hemp leaf, hemp floral material, including but not limited to hemp cigars or hemp cigarettes, viable seeds (this does not apply to sale of hemp leaf, hemp floral material, or viable seeds to a USDA licensed hemp producer or a DOH permitted hemp processor); MHP containing any viable seeds, leaf or floral materials; Except for external topically applied MHP, any product containing a hemp-derived cannabinoid, artificially derived cannabinoid, synthetic cannabinoid, hemp, hemp biomass, or MHP as an ingredient intended to be introduced via non-oral routes of entry to body (i.e. eyes, ears and nasal cavities, etc.); Crude extract directly to a consumer (crude extract shall only be sold to a permitted hemp processor or person with equivalent authority from regulatory agency in another jurisdiction); Contents from an open package of MHP to a consumer; Advertising, packaging, labeling that contains health or benefit claims that are unsubstantiated, false, or misleading in any way. DOH implementing guidance (Consumers of MHP FAQ, current 12/16/2025): 'Hawaii prohibits the sale of MHP that contain artificially derived or synthetic cannabinoids. This includes cannabinoids like delta-8 THC, delta-10 THC, THCO, THC-P, THC-H, THCjd, HHC, HHCO, CBN created from any naturally occurring cannabinoid, like CBD, that was extracted from hemp biomass, or using a non-hemp substance, like yeast or algae, to produce any cannabinoid. State law only allows for cannabinoids naturally occurring in hemp to be extracted for use in manufactured hemp products.'
fbf286ee4ef617a2**Schedule gap — § 329-14(d):** "Hallucinogenic substances … any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers … (14) Diethyltryptamine; (15) Dimethyltryptamine; … (26) Psilocybin; (27) Psilocyn; … (37) Alpha-methyltryptamine (AMT); (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT)." (4-HO-MET not named; no structural class; isomer-only catch-all does not reach a homolog.) — HRS § 329-14(d); via labeled Justia mirror (2025): https://law.justia.com/codes/hawaii/title-19/chapter-329/section-329-14/ **No analog definition — HRS § 329-1 (full definitions retrieved):** "'Controlled substance' means a drug, substance, or immediate precursor in schedules I through V of part II." The section's A–Z definitions contain **no** "controlled substance analog" / "substantially similar" entry. — HRS § 329-1; via labeled Justia mirror (2025), full section read: https://law.justia.com/codes/hawaii/title-19/chapter-329/section-329-1/
823a943b28b715deAs used in this chapter: "Applicant" means the person applying to register as a hemp processor under this chapter. "Cannabinoids" means any of the various naturally occurring, biologically active, chemical constituents of cannabis that bind to or interact with receptors of the endogenous cannabinoid system. "Cannabis" means the genus of the flowering plant in the family Cannabaceae. For the purpose of this chapter, cannabis refers to any form of the plant where the delta-9 tetrahydrocannabinol concentration on a dry weight basis has not yet been determined. "Certificate of registration" means the certificate issued by the department attesting that the applicant is registered to process hemp. "Decarboxylated" means the completion of the chemical reaction that converts delta-9 tetrahydrocannabinol's acids (THCA) into delta-9-tetrahydrocannabinol. The decarboxylated value may be calculated using a conversion formula that sums delta-9-tetrahydrocannabinol and eighty-seven and seven tenths (87.7) per cent of THCA. "Delta-9 tetrahydrocannabinol" or "THC" means the primary psychoactive component of cannabis. "Department" means the department of health. "Director" means the director of health. "Dry weight basis" refers to a method of determining the percentage of a chemical in a substance after removing the moisture from the substance. "Enclosed indoor facility" means a permanent, stationary structure with a solid floor, rigid exterior walls that encircle the entire structure on all sides, and a roof that protects the entire interior area from the elements of weather. Nothing in this definition shall be construed to relieve the registered applicant from the applicant's duty to comply with all applicable building codes and regulations. "FDA" means the United States Food and Drug Administration. "Hemp" means Cannabis sativa L. and any part of that plant, whether growing or not, including the seeds thereof and all derivatives, extracts, cannabinoids, isomers, acids, salts, and salts of isomers, with a delta-9-tetrahydrocannabinol concentration of not more than 0.3 per cent on a dry weight basis, as measured post-decarboxylation or by other similarly reliable methods. "Hemp processor" means a person processing hemp to manufacture a hemp product. "Hemp product" means a product that: (1) Contains naturally occurring cannabinoids, compounds, concentrates, extracts, isolates, resins or derivatives from processed hemp; (2) Does not include any living hemp plants, viable seeds, leaf materials, or floral materials; (3) Has a delta-9-tetrahydrocannabinol concentration of not more than 0.3 per cent, as measured post-decarboxylation, or other similarly reliable methods; (4) Is intended to be consumed orally to supplement the human or animal diet; and (5) Is in the form of a tablet, capsule, powder, softgel, gelcap, or liquid form (e.g. hemp oil) to be used by the consumer to infuse edible items at home for personal use or for topical application to the skin or hair. For purposes of this chapter, a hemp product shall be considered as intended for oral ingestion in liquid form only if it is formulated in a fluid carrier and it is intended for ingestion in daily quantities measured in drops or similar small units of measure per labeled directions for use. "Manufacture" means to compound, blend, extract, infuse, or otherwise make or prepare a hemp product, but does not include planting, growing, harvesting, drying, curing, grading, or trimming a hemp plant or part of a hemp plant. "Person" means an individual, firm, corporation, partnership, association, or any form of business or legal entity. "Processing" means making a transformative change to the hemp plant following harvest by converting an agricultural commodity into a hemp product. "Synthetic cannabinoid" means a cannabinoid that is: (1) Produced artificially, whether from chemicals or from recombinant biological agents including but not limited to yeast and algae; and (2) Not derived from the genus cannabis, including biosynthetic cannabinoids.
04a4a24d2429287a§329-14 Schedule I. (a) The controlled substances listed in this section are included in schedule I. (b) Opiates. Unless specifically excepted or unless listed in another schedule, any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, whenever the existence of these isomers, esters, ethers, and salts is possible within the specific chemical designation: (1) Acetyl-alpha-methylfentanyl (N-[1-(1-methyl-2-phenethyl)-4-piperidinyl]-N-phenylacetamide); (2) Acetylmethadol; (3) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide), its optical, positional, and geometric isomers, salts, and salts of isomers; (4) Acryl fentanyl [N-(1-phenethylpiperidin-4-yl)-N-phenylacrylamide] (Other name: acryloylfentanyl); (5) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)cyclohexylmethyl]benzamide); (6) Allylprodine; (7) Alphacetylmethadol (except levo-alphacetylmethadol, levomethadyl acetate, or LAAM); (8) Alphameprodine; (9) Alphamethadol; (10) Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide); (11) Alpha-methylfentanyl (N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide; 1-(1-methyl-2-phenylethyl)-4-(N-propanilido)piperidine); (12) Alpha-methylthiofentanyl (N-[1-methyl-2-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); (13) Benzethidine; (14) Benzylfentanyl (N-[1-benzyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers; (15) Betacetylmethadol; (16) Beta-hydroxyfentanyl (N-[1-(2-hydroxy-2-phenethyl)-4-piperidinyl]-N-phenylpropanamide); (17) Beta-hydroxy-3-methylfentanyl (N-[1-(2-hydroxy-2-phenethyl)-3-methyl-4-piperidinyl]-N-phenylpropanamide); (18) Beta-hydroxythiofentanyl (N-[1-[2-hydroxy-2-(thiophen-2-yl)ethyl]piperidin-4-yl]-N-phenylpropionamide); (19) Betameprodine; (20) Betamethadol; (21) Beta-methyl fentanyl (N-phenyl-N-(1-(2-phenylpropyl)piperidin-4-yl)propionamide) (Other name: [beta]-methyl fentanyl); (22) Beta'-phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N,3-diphenylpropanamide) (Other names: [beta]'-phenyl fentanyl; 3-phenylpropanoyl fentanyl); (23) Betaprodine; (24) Brorphine (1-(1-(1-(4-bromophenyl)ethyl)piperidin-4-yl)-1,3-dihydro-2H-benzo[d]imidazol-2-one); (25) Butonitazene (2-(2-(4-butoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine); (26) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbutyramide); (27) Clonitazene; (28) Crotonyl fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide); (29) Cyclopentyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopentanecarboxamide); (30) Cyclopropyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide); (31) Dextromoramide; (32) Diampromide; (33) Diethylthiambutene; (34) Difenoxin; (35) Dimenoxadol; (36) Dimepheptanol; (37) 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide); (38) Dimethylthiambutene; (39) Dioxaphetyl butyrate; (40) Dipipanone; (41) Ethylmethylthiambutene; (42) Etodesnitazene (2-(2-(4-ethoxybenzyl)-1H-benzimidazol-1-yl)-N,N-diethylethan-1-amine) (Other name: etazene); (43) Etonitazene; (44) Etoxeridine; (45) Fentanyl carbamate (ethyl (1-phenethylpiperidin-4-yl)(phenyl)carbamate); (46) Flunitazene (N,N-diethyl-2-(2-(4-fluorobenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); (47) 4-fluoroisobutyryl fentanyl [N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide] (Other name: para-fluoroisobutyryl fentanyl); (48) 2'-fluoro ortho-fluorofentanyl (N-(1-(2-fluorophenethyl)piperidin-4-yl)-N-(2-fluorophenyl)propionamide) (Other name: 2'-fluoro 2-fluorofentanyl); (49) Furanyl fentanyl (N-(1-phenethylpiperidin-4-y1)-N-phenylfuran-2-carboxamide); (50) 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide); (51) Furethidine; (52) Hydroxypethidine; (53) Isobutyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylisobutyramide); (54) Isotonitazene (N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); (55) Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide); (56) Ketobemidone; (57) Levomoramide; (58) Levophenacylmorphan; (59) Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide); (60) Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); (61) Methoxyacetyl fentanyl (2-methoxy-N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide); (62) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one); (63) 4'-methyl acetyl fentanyl (N-(1-(4-methylphenethyl)piperidin-4-yl)-N-phenylacetamide); (64) 3-methylfentanyl (N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide); (65) 3-methylthiofentanyl (N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide); (66) Metodesnitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine); (67) Metonitazene (N,N-diethyl-2-(2-(4-methoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine); (68) Morpheridine; (69) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine); (70) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine); (71) Noracymethadol; (72) Norlevorphanol; (73) Normethadone; (74) Norpipanone; (75) N-pyrrolidino etonitazene (2-(4-ethoxybenzyl)-5-nitro-1-(2-(pyrrolidin-1-yl)ethyl)-1H-benzimidazole) (Other name: etonitazepyne); (76) Ocfentanil [N-(2-fluorophenyl)-2-methoxy-N-(1-phenethylpiperidin-4-yl)acetamide]; (77) Ortho-fluoroacryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)acrylamide); (78) Ortho-fluorobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide) (Other name: 2-fluorobutyryl fentanyl); (79) Ortho-fluorofentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 2-fluorofentanyl); (80) Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide); (81) Ortho-fluoroisobutyryl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); (82) Ortho-methyl acetylfentanyl (N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl acetylfentanyl); (83) Ortho-methyl methoxyacetyl fentanyl (2-methoxy-N-(2-methylphenyl)-N-(1-phenethylpiperidin-4-yl)acetamide) (Other name: 2-methyl methoxyacetyl fentanyl); (84) Para-chloroisobutyryl fentanyl (N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide); (85) Para-fluorobutyryl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); (86) Para-fluorofentanyl (N-(4-fluorophenyl)-N-[1-(2-phenethyl)-4-piperidinyl]propanamide); (87) Para-fluoro furanyl fentanyl (N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide); (88) Para-methoxybutyryl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)butyramide); (89) Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide); (90) Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide); (91) Para-methylfentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)propionamide) (Other name: 4-methylfentanyl); (92) PEPAP (1-(-2-phenethyl)-4-phenyl-4-acetoxypiperidine); (93) Phenadoxone; (94) Phenampromide; (95) Phenomorphan; (96) Phenoperidine; (97) Phenyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylbenzamide) (Other name: benzoyl fentanyl); (98) Piritramide; (99) Proheptazine; (100) Properidine; (101) Propiram; (102) Protonitazene (N,N-diethyl-2-(5-nitro-2-(4-propoxybenzyl)-1H-benzimidazol-1-yl)ethan-1-amine); (103) Racemoramide; (104) Tetrahydrofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide); (105) Thenylfentanyl (N-[1-(2-thienyl)methyl-4-piperidyl]-N-phenylpropanamide), its optical isomers, salts, and salts of isomers; (106) Thiofentanyl (N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide); (107) Thiofuranyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylthiophene-2-carboxamide) (Other names: 2-thiofuranyl fentanyl; thiophene fentanyl); (108) Tilidine; (109) Trimeperidine; (110) U-47700 (3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methylbenzamide); and (111) Valeryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylpentanamide). (c) Any of the following opium derivatives, their salts, isomers, and salts of isomers, unless specifically excepted, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Acetorphine; (2) Acetyldihydrocodeine; (3) Benzylmorphine; (4) Codeine methylbromide; (5) Codeine-N-Oxide; (6) Cyprenorphine; (7) Desomorphine; (8) Dihydromorphine; (9) Drotebanol; (10) Etorphine; (11) Heroin; (12) Hydromorphinol; (13) Methyldesorphine; (14) Methyldihydromorphine; (15) Morphine methylbromide; (16) Morphine methylsulfonate; (17) Morphine-N-Oxide; (18) Myrophine; (19) Nicocodeine; (20) Nicomorphine; (21) Normorphine; (22) Phoclodine; and (23) Thebacon. (d) Hallucinogenic substances. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following hallucinogenic substances, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Alpha-ethyltryptamine (AET); (2) 2,5-dimethoxy-4-ethylamphetamine (DOET); (3) 2,5-dimethoxyamphetamine (2,5-DMA); (4) 3,4-methylenedioxy amphetamine; (5) 3,4-methylenedioxymethamphetamine (MDMA); (6) N-hydroxy-3,4-methylenedioxyamphetamine (N-hydroxy-MDA); (7) 3,4-methylenedioxy-N-ethylamphetamine (MDE); (8) 5-methoxy-3,4-methylenedioxy-amphetamine; (9) 4-bromo-2,5-dimethoxy-amphetamine (4-bromo-2,5-DMA); (10) 4-Bromo-2,5-dimethoxyphenethylamine (Nexus); (11) 3,4,5-trimethoxy amphetamine; (12) Bufotenine; (13) 4-methoxyamphetamine (PMA); (14) Diethyltryptamine; (15) Dimethyltryptamine; (16) 4-methyl-2,5-dimethoxy-amphetamine; (17) Gamma hydroxybutyrate (GHB) (some other names include gamma hydroxybutyric acid; 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate); (18) Ibogaine; (19) Lysergic acid diethylamide; (20) Marijuana; (21) Parahexyl; (22) Mescaline; (23) Peyote; (24) N-ethyl-3-piperidyl benzilate; (25) N-methyl-3-piperidyl benzilate; (26) Psilocybin; (27) Psilocyn; (28) 1-[1-(2-Thienyl) cyclohexyl] Pyrrolidine (TCPy); (29) Ethylamine analog of phencyclidine (PCE); (30) Pyrrolidine analog of phencyclidine (PCPy, PHP); (31) Thiophene analog of phencyclidine (TPCP; TCP); (32) Gamma-butyrolactone, including butyrolactone; butyrolactone gamma; 4-butyrolactone; 2(3H)-furanone dihydro; dihydro-2(3H)furanone; tetrahydro-2-furanone; 1,2-butanolide; 1,4-butanolide; 4-butanolide; gamma-hydroxybutyric acid lactone; 3-hydroxybutyric acid lactone and 4-hydroxybutanoic acid lactone with Chemical Abstract Service number 96-48-0 when any such substance is intended for human ingestion; (33) 1,4 butanediol, including butanediol; butane-1,4-diol; 1,4- butylenes glycol; butylene glycol; 1,4-dihydroxybutane; 1,4- tetramethylene glycol; tetramethylene glycol; tetramethylene 1,4- diol with Chemical Abstract Service number 110-63-4 when any such substance is intended for human ingestion; (34) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7), its optical isomers, salts, and salts of isomers; (35) N-benzylpiperazine (BZP; 1-benzylpiperazine), its optical isomers, salts, and salts of isomers; (36) 1-(3-trifluoromethylphenyl)piperazine (TFMPP), its optical isomers, salts, and salts of isomers; (37) Alpha-methyltryptamine (AMT); (38) 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT); (39) Salvia divinorum; (40) Salvinorin A; (41) Divinorin A; (42) 5-Methoxy-N,N-Dimethyltryptamine (some trade or other names: 5-methoxy-3-[2-(dimethylamino)ethyl]indole; 5-MeO-DMT); (43) 2-(2,5-Dimethoxy-4-ethylphenyl)ethanamine (2C-E); (44) 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (2C-D); (45) 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (2C-C); (46) 2-(4-Iodo-2,5-dimethoxyphenyl)ethanamine (2C-I); (47) 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-2); (48) 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (2C-T-4); (49) 2-(2,5-Dimethoxyphenyl)ethanamine (2C-H); (50) 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (2C-N); (51) 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (2C-P); (52) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25I-NBOMe; 2C-I-NBOMe; 25I; Cimbi-5); (53) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25C-NBOMe; 2C-C-NBOMe; 25C; Cimbi-82); (54) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-methoxybenzyl)ethanamine, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 25B-NBOMe; 2C-B-NBOMe; 25B; Cimbi-36); (55) N-ethylhexedrone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-ethylaminohexanophenone; 2-(ethylamino)-1-phenylhexan-1-one); (56) Alpha-pyrrolidinohexanophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: [alpha]-PHP; [alpha]-pyrrolidinohexanophenone; 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one); (57) 4-methyl-alpha-ethylaminopentiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-MEAP; 2-(ethylamino)-1-(4-methylphenyl)pentan-1-one); (58) 4'-methyl-alpha-pyrrolidinohexiophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: MPHP; 4'-methyl-alpha-pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-yl)hexan-1-one); (59) Alpha-pyrrolidinoheptaphenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-yl)heptan-1-one); (60) 4'-chloro-alpha-pyrrolidinovalerophenone, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 4-chloro-[alpha]-PVP; 4'-chloro-[alpha]-pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-yl)pentan-1-one); (61) 2-(ethylamino)-2-(3-methoxyphenyl)cyclohexan-1-one (methoxetamine, MXE); (62) Eutylone (1-(1,3-benzodioxol-5-yl)-2-(ethylamino)butan-1-one) (Other name: bk-EBDB); (63) Zipeprol (1-methoxy-3-[4-(2-methoxy-2-phenylethyl)piperazin-1-yl]-1-phenylpropan-2-ol), including its isomers, esters, ethers, salts, and salts of isomers, esters and ethers, whenever the existence of such isomers, esters, ethers and salts is possible within the specific chemical designation; (64) (1-pentyl-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (UR-144); (65) [1-(5-fluoro-pentyl)-1 H -indol-3-yl](2,2,3,3-tetramethylcyclopropyl)methanone (5-fluoro-UR-144, XLR11); (66) N -(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1 H -indazole-3-carboxamide (Other name: ADB-FUBINACA); (67) Methyl 2-(1-(cyclohexylmethyl)-1 H -indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: MDMB-CHMICA, MMB-CHMINACA); (68) Methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: MDMB-FUBINACA); and (69) N-ethylpentylone (Other names: ephylone, 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)pentan-1-one). (e) Depressants. Unless specifically excepted, the schedule shall include any material, compound, mixture, or preparation which contains any quantity of the substance: (1) Mecloqualone; (2) Methaqualone; (3) Etizolam (including its optical, positional, and geometric isomers, salts, and salts of isomers, where possible); or (4) Flualprazolam (including its optical, positional, and geometric isomers, salts, and salts of isomers, where possible). (f) Stimulants. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a stimulant effect on the central nervous system, including its salts, isomers, and salts of isomers: (1) Amineptine (7-[(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-yl)amino]heptanoic acid); (2) Aminorex; (3) Cathinone; (4) 4,4'-dimethylaminorex (common name: 4,4'-DMAR); (5) Ethylphenidate (ethyl 2-phenyl-2-(piperidin-2-yl)acetate); (6) Fenethylline; (7) Mesocarb (N-phenyl-N' -(3-(1-phenylpropan-2-yl)-1,2,3-oxadiazol-3-ium-5-yl)carbamimidate); (8) Methcathinone; (9) Methiopropamine (N-methyl-1-(thiophen-2-yl)propan-2-amine); (10) 4-methylaminorex; (11) N-ethylamphetamine; (12) N,N-dimethylamphetamine; (13) Substituted cathinones, any compound, except bupropion or compounds listed under a different schedule, structurally derived from 2-aminopropan-1-one by substitution at the 1-position with either phenyl, naphthyl, or thiophene ring systems, whether or not the compound is further modified in any of the following ways: (A) By substitution in the ring system to any extent with alkyl, alkylenedioxy, alkoxy, haloalkyl, hydroxyl, or halide substituents, whether or not further substituted in the ring system by one or more other univalent substituents; (B) By substitution at the 3-position with an acyclic alkyl substituent; or (C) By substitution at the 2-amino nitrogen atom with alkyl, dialkyl, benzyl, or methoxybenzyl groups, or by inclusion of the 2-amino nitrogen atom in a cyclic structure. Some other trade names: Mephedrone (2-methylamino-1-p-tolylpropan-1-one), also known as 4-methylmethcathinone (4-MMC), methylephedrone or MMCAT; Methylenedioxypyrovalerone (MDPV, MDPK); methylone or 3,4-methylenedioxymethcathinone; and 1-(benzo[d][1,3]dioxol-5-yl)-2-(ethylamino)propan-1-one, monohydrochloride, also known as Ethylone, bk-MDEA hydrochloride, MDEC; 3,4-Methylenedioxy-N-ethylcathinone; bk-Methylenedioxyethylamphetamine, 4-methyl-N-ethylcathinone (4-MEC); 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP); alpha-pyrrolidinopentiophenone ([alpha]-PVP); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one (butylone, bk-MBDB e); 2-(methylamino)-1-phenylpentan-1-one (pentedrone); 1-(1,3-benzodioxol-5-yl)-2-(methylamino)pentan-1-one (pentylone, bk-MBDP); 4-fluoro-N-methylcathinone (4-FMC, flephedrone); 3-fluoro-N-methylcathinone (3-FMC); 1-(naphthalen-2-yl)-2-(pyrrolidin-1-yl)pentan-1-one (naphyrone); alpha-pyrrolidinobutiophenone ([alpha]-PBP) and their optical, positional, and geometric isomers, salts and salts of isomers, whenever the existence of such salts, isomers, and salts of isomers is possible; and (14) 1-(4-methoxyphenyl)-N-methylpropan-2-amine (Other names: para-methoxymethamphetamine; PMMA). (g) Cannabinoids. Unless specifically excepted or unless listed in another schedule, any of the following cannabinoids, including their salts, isomers, and salts of isomers, whenever the existence of these salts, isomers, and salts of isomers is possible within the specific chemical designation: (1) Tetrahydrocannabinols ; meaning tetrahydrocannabinols naturally contained in a plant of the genus Cannabis (cannabis plant), as well as synthetic equivalents of the substances contained in the plant, or in the resinous extractives of Cannabis, sp. or synthetic substances, derivatives, and their isomers with similar chemical structure and pharmacological activity to those substances contained in the plant, such as the following: Delta 1 cis or trans tetrahydrocannabinol, and their optical isomers; Delta 6 cis or trans tetrahydrocannabinol, and their optical isomers; and Delta 3,4 cis or trans-tetrahydrocannabinol, and its optical isomers (since nomenclature of these substances is not internationally standardized, compounds of these structures, regardless of numerical designation of atomic positions, are covered); (2) Naphthoylindoles; meaning any compound containing a 3-(1-naphthoyl)indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (3) Naphthylmethylindoles; meaning any compound containing a 1H-indol-3-yl-(1-naphthyl) methane structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the naphthyl ring to any extent; (4) Naphthoylpyrroles; meaning any compound containing a 3-(1-naphthoyl)pyrrole structure with substitution at the nitrogen atom of the pyrrole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the pyrrole ring to any extent, whether or not substituted in the naphthyl ring to any extent; (5) Naphthylmethylindenes; meaning any compound containing a naphthylideneindene structure with substitution at the 3-position of the indene ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indene ring to any extent, whether or not substituted in the naphthyl ring to any extent; (6) Phenylacetylindoles; meaning any compound containing a 3-phenylacetylindole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl , alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent, whether or not substituted in the phenyl ring to any extent; (7) Cyclohexylphenols ; meaning any compound containing a 2-(3-hydroxycyclohexyl) phenol structure with substitution at the 5-position of the phenolic ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl or 2-(4-morpholinyl) ethyl group whether or not substituted in the cyclohexyl ring to any extent; (8) Benzoylindoles; meaning any compound containing a 3-( benzoyl ) indole structure with substitution at the nitrogen atom of the indole ring by a alkyl, haloalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl) methyl, or 2-(4-morpholinyl) ethyl group whether or not further substituted in the indole ring to any extent and whether or not substituted in the phenyl ring to any extent; (9) [2,3-Dihydro-5-methyl-3-(4-morpholinylmethyl) pyrrolo[1,2,3-de]-1, 4-benzoxazin-6-yl]-1-naphthalenylmethanone (another trade name is WIN 55,212-2); (10) (6a,10a)-9-(hydroxymethyl)-6, 6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tetrahydrobenzo[c]chromen-1-ol (Other trade names are: HU-210/HU-211); (11) Tetramethylcyclopropanoylindoles; meaning any compound containing a 3-tetramethylcyclopropanoylindole structure with substitution at the nitrogen atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl, 2-(4-morpholinyl)ethyl, 1-(N-methyl-2-pyrrolidinyl)methyl, 1-(N-methyl-3-morpholinyl)methyl, or tetrahydropyranylmethyl group, whether or not further substituted in the indole ring to any extent and whether or not substituted in the tetramethylcyclopropyl ring to any extent; (12) N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: APINACA, AKB48); (13) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: PB-22; QUPIC); (14) Quinolin-8-yl 1-(5fluoropentyl)-1H-indole-3-carboxylate, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-PB-22; 5F-PB-22); (15) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-FUBINACA); (16) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: ADB-PINACA); (17) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: AB-CHMINACA); (18) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AB-PINACA); (19) [1-(5-fluoropentyl)-1H-indazol-3-yl](naphthalen-1-yl)methanone, and geometric isomers, salts, and salts of isomers (Other names: THJ-2201); (20) Methyl (1-(4-fluorobenzyl)-1H-indazole-3-carbonyl)-L-valinate, and geometric isomers, salts, and salts of isomers (Other names: FUB-AMB, M ethyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, MMB-FUBINACA, AMB-FUBINACA ); (21) (S)-methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate, and geometric isomers, salts, and salts of isomers (Other names: 5-fluoro-AMB, 5-fluoro-AMP); (22) N-((3s,5s,7s)-adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: AKB48 N-(5-fluoropentyl) analog, 5F-AKB48, APINACA 5-fluoropentyl analog, 5F-APINACA); (23) N-adamantyl-1-fluoropentylindole-3-Carboxamide, and geometric isomers, salts, and salts of isomers (Other names: STS-135, 5F-APICA; 5-fluoro-APICA); (24) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-carboxylate, and geometric isomers, salts, and salts of isomers (Other names: NM2201; CBL2201); (25) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide, and geometric isomers, salts, and salts of isomers (Other names: MAB-CHMINACA and ADB-CHMINACA); (26) Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (Other names: 5F-ADB, 5-fluoro-ADB, and 5F-MDMB-PINACA), its optical, positional, and geometric isomers, salts, and salts of isomers; (27) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide, its optical, positional, and geometric isomers, salts, and salts of isomers (Other names: SGT-78; 4-CN-CUMYL BINACA; 4-CN-CUMYL-BUTINACA; CUMYL-CB-PINACA; CUMYL-CYBINACA; 4-cyano-CUMYL-BUTINACA; CUMYL-4CN-BINACA); (28) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (Other name: 5F-AB-PINACA); (29) Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3-methylbutanoate (Other names: MMB-CHMICA; AMB-CHMICA); (30) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide (Other names: 5F-CUMYL-P7AICA); (31) Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate (MDMB-4en-PINACA); (32) Ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3,3-dimethylbutanoate (Other name: 5F-EDMB-PINACA); (33) Methyl 2-(1-(5-fluoropentyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (Other names: 5F-MDMB-PICA; 5F-MDMB-2201); (34) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (Other names: FUB-AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL)); (35) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide (Other names: 5F-CUMYL-PINACA; SGT-25); and (36) (1-(4-fluorobenzyl)-1H-indol-3-yl)(2,2,3,3-tetramethylcyclopropyl)methanone (Other name: FUB-144). [L 1972, c 10, pt of §1; am L 1974, c 217, §1; am L 1977, c 116, §1; am L 1978, c 68, §2; am L 1979, c 194, §1; am L 1980, c 140, §1 and c 232, §16; am L 1984, c 166, §1; am L 1985, c 150, §1; am L 1986, c 214, §§2, 3; am L 1988, c 59, §1; am L 1990, c 138, §3; am L 1993, c 8, §1; am L 1995, c 122, §1; am L 1997, c 356, §1; am L 1999, c 252, §2; am L 2000, c 98, §1; am L 2001, c 203, §2; am L 2003, c 151, §§1, 2; am L 2008, c 119, §3; am L 2010, c 123, §1; am L 2011, c 73, §1; am L 2012, c 29, §1; am L 2013, c 48, §1; am L 2014, c 54, §1; am L 2015, c 195, §1; am L 2016, c 218, §§2, 3; am L 2017, c 155, §1; am L 2018, c 190, §1; am L 2020, c 27, §2 and c 70, §48; am L 2021, c 233, §1; am L 2022, c 106, §1; am L 2023, c 162, §1; am L 2025, c 107, §1] Case Notes Proscription of distribution of lysergic acid "diethylamine" under this section (1974) cannot be extended by analogy under §701-104 to distribution of lysergic acid diethylamide. 61 H. 74, 595 P.2d 288 (1979). Previous Vol06_Ch0321-0344 Next
Compound Laws, published by Compound Analytics, reports the record: statutes verbatim, official citations, enforcement facts and verification dates. Nothing here is legal advice and nothing here describes how to get around a law. A jurisdiction with no verified row is reported as not yet verified, never as legal. Found an error? Corrections policy.
About · Methodology · Glossary · Changes · Data & API · llms.txt · Sitemap